Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1312"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label |
"evidence_1060"
|
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| dc:creator | |
| dc:date |
"09/24/2009 14:28:51"
|
| ?:content |
"Excretion In neonates, approximately 50% of the theophylline dose is excreted unchanged in the urine. Beyond the first three months of life, approximately 10% of the theophylline dose is excreted unchanged in the urine. The remainder is excreted in the urine mainly as 1,3-dimethyluric acid (35-40%), 1-methyluric acid (20-25%) and 3-methylxanthine (15-20%). Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children >3 months of age. In contrast, the large fraction of the theophylline dose excreted in the urine as unchanged theophylline and caffeine in neonates requires careful attention to dose reduction and frequent monitoring of serum theophylline concentrations in neonates with reduced renal function"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ theophylline_primary_total_clearance_mechanism_Metabolic_Clearance, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1060 }